Vetoquinol Ord(VETOF)
USD --+0.00%
Reward49Moderate
Risk36Moderate
📊75%Data
VETOF
+0.0 · +0.00%
USD · PINK
Vetoquinol Ord | Healthcare
Deep Value
Market Cap:1.03Bn
ℹ️
Reward Rating
49
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
36
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on VETOF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Vetoquinol Ord?

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region.

VETOF · Verdict

Moderate reward · moderate risk

VETOF stands out on cash flow and profitability, but watch the growth signal.

Based on 88% data coverage

VETOF · Verdict

What’s working & what to watch

Strengths 2

  • Cash flow86/100

    13% free-cash-flow margin

  • Profitability73/100

    11% net margin · 11% ROE

Watchouts 1

  • Growth32/100

    Rev +1.1% CAGR · earnings -2.3%

Model-based scoring. For information only — not financial advice.

What is Vetoquinol Ord?

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.03B, and a P/E ratio of 15.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (49)

The scoring profile indicates limited reward potential at this time, with profitability and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.03B
P/E Ratio15.2191
Dividend Yield1.02%
52 Week High87.51
52 Week Low54.2721
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding12M
No. of Employees2,497
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta1.02
CurrencyUSD · Reports in EUR